Anti-Angiogenic Drug for HCC: STAM model
We would like to focus on Hepatocellular Carcinoma (HCC).
Tumor angiogenesis plays a crucial role in supplying a tumor with oxygen and nutrients to sustain optimal growth.
As HCC is a typical hypervascular tumor that forms a network of blood vessels, inhibiting tumor angiogenesis is expected to be useful in the treatment of HCC.
KEYWORD:Hepatocellular Carcinoma, Liver Cancer, Combination Therapy
In this study, the authors demonstrated that Sorafenib monotherapy and combination with S-1(Tegafur-Gimeracil-Oteracil) resulted in a decreasing the number of tumors using our MASH-HCC model (STAM™). In addition, the tumor microvessel density (CD31 staining), a marker of tumor angiogenesis, was decreased as well (Suzuki et al. Transl Oncol. 2021.)
Current drugs for HCC, such as Sorafenib, Lenvatinib and Bevacizumab are targeting the inhibition of tumor angiogenesis.